| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Departments of
*
Cell Biology and
Anatomy, Faculty of Medical Sciences, University of Nijmegen, Nijmegen, The Netherlands;
Imperial Cancer Research Fund Tumour Immunology Unit, University College London Medical School, London, United Kingdom;
§
The Edward Jenner Institute for Vaccine Research, Compton, Newbury, United Kingdom; and
¶
Institute of Molecular Medicine, John Radcliffe Hospital, Headington, Oxford, United Kingdom
CD45 is a transmembrane glycoprotein possessing tyrosine phosphatase activity, which is involved in cell signaling. CD45 is expressed on the surface of most leukocytes and can be alternatively spliced by the inclusion or skipping of three variable exons (4, 5, and 6 or A, B, and C) to produce up to eight isoforms. In T cells, the splicing pattern of CD45 isoforms changes after activation; naive cells express high m.w. isoforms of CD45 which predominantly express exon A (CD45RA), whereas activated cells lose expression of exon A to form low m.w. isoforms of CD45 including CD45RO. Little is known about the specific factors controlling the switch in CD45 splicing which occurs on activation. In this study, we examined the influence of the SR family of splicing factors, which, like CD45, are expressed in tissue-specific patterns and have been shown to modulate the alternative splicing of a variety of transcripts. We show that specific SR proteins have antagonistic effects on CD45 splicing, leading either to exon inclusion or skipping. Furthermore, we were able to demonstrate specific changes in the SR protein expression pattern during T cell activation.
This article has been cited by other articles:
|
|
 |
|
  T. Revil, J. Toutant, L. Shkreta, D. Garneau, P. Cloutier, and B. Chabot Protein Kinase C-Dependent Control of Bcl-x Alternative Splicing Mol. Cell. Biol., December 15, 2007; 27(24): 8431 - 8441. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Buratti, C. Stuani, G. De Prato, and F. E. Baralle SR protein-mediated inhibition of CFTR exon 9 inclusion: molecular characterization of the intronic splicing silencer Nucleic Acids Res., July 26, 2007; 35(13): 4359 - 4368. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Y. Ip, A. Tong, Q. Pan, J. D. Topp, B. J. Blencowe, and K. W. Lynch Global analysis of alternative splicing during T-cell activation RNA, April 1, 2007; 13(4): 563 - 572. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Massiello and C. E. Chalfant SRp30a (ASF/SF2) regulates the alternative splicing of caspase-9 pre-mRNA and is required for ceramide-responsiveness J. Lipid Res., May 1, 2006; 47(5): 892 - 897. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F.-J. Li, N. Tsuyama, H. Ishikawa, M. Obata, S. Abroun, S. Liu, K.-i. Otsuyama, X. Zheng, Z. Ma, Y. Maki, et al. A rapid translocation of CD45RO but not CD45RA to lipid rafts in IL-6-induced proliferation in myeloma Blood, April 15, 2005; 105(8): 3295 - 3302. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. R. BRUCE, R.W. C. DINGLE, and M. L. PETERSON B-cell and plasma-cell splicing differences: A potential role in regulated immunoglobulin RNA processing RNA, October 1, 2003; 9(10): 1264 - 1273. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Suarez, L. Mozo, and C. Gutierrez Generation of CD4+CD45RA+ Effector T Cells by Stimulation in the Presence of Cyclic Adenosine 5'-Monophosphate- Elevating Agents J. Immunol., August 1, 2002; 169(3): 1159 - 1167. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. J. Smith, E. L. Spurrell, J. Coakley, C. J. Hinds, R. J. M. Ross, A. R. Krainer, and S. L. Chew An Exonic Splicing Enhancer in Human IGF-I Pre-mRNA Mediates Recognition of Alternative Exon 5 by the Serine-Arginine Protein Splicing Factor-2/ Alternative Splicing Factor Endocrinology, January 1, 2002; 143(1): 146 - 154. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. W. Lynch and A. Weiss A CD45 Polymorphism Associated with Multiple Sclerosis Disrupts an Exonic Splicing Silencer J. Biol. Chem., June 22, 2001; 276(26): 24341 - 24347. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
